Yasha S. Modi, MD, MHS

Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.